Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Opus Genetics (IRD) Operating Income (2020 - 2026)

Opus Genetics has reported Operating Income over the past 12 years, most recently at -$14.4 million for Q1 2026.

  • Quarterly Operating Income fell 44.67% to -$14.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$43.0 million through Mar 2026, up 33.07% year-over-year, with the annual reading at -$38.6 million for FY2025, 37.82% up from the prior year.
  • Operating Income was -$14.4 million for Q1 2026 at Opus Genetics, down from -$11.5 million in the prior quarter.
  • Over five years, Operating Income peaked at $34.2 million in Q4 2022 and troughed at -$38.0 million in Q4 2024.
  • The 5-year median for Operating Income is -$7.7 million (2024), against an average of -$6.3 million.
  • Year-over-year, Operating Income soared 656.26% in 2022 and then tumbled 600.48% in 2024.
  • A 5-year view of Operating Income shows it stood at $34.2 million in 2022, then plummeted by 115.87% to -$5.4 million in 2023, then tumbled by 600.48% to -$38.0 million in 2024, then soared by 69.88% to -$11.5 million in 2025, then fell by 25.42% to -$14.4 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Operating Income are -$14.4 million (Q1 2026), -$11.5 million (Q4 2025), and -$8.3 million (Q3 2025).